6,129 Shares of Illumina, Inc. $ILMN Bought by Virtue Capital Management LLC

Virtue Capital Management LLC acquired a new stake in Illumina, Inc. (NASDAQ:ILMN) in the 3rd quarter, Holdings Channel.com reports. The fund acquired 6,129 shares of the life sciences company’s stock, valued at approximately $1,677,000.

Other large investors have also added to or reduced their stakes in the company. BlackRock Inc. bought a new position in shares of Illumina during the second quarter valued at $3,374,423,000. Plato Investment Management Ltd acquired a new position in shares of Illumina during the second quarter worth $948,000. Mitsubishi UFJ Asset Management Co. Ltd. bought a new stake in shares of Illumina in the second quarter worth $30,501,000. Edmond DE Rothschild Holding S.A. bought a new stake in shares of Illumina in the second quarter worth $129,792,000. Finally, OVERSEA CHINESE BANKING Corp Ltd bought a new stake in shares of Illumina in the second quarter worth $6,711,000. Institutional investors own 89.42% of the company’s stock.

More Illumina News

Here are the key news stories impacting Illumina this week:

• Positive Sentiment: Adjusted earnings exceeded expectations. Illumina reported third-quarter adjusted EPS of $1.44, above the $1.36 consensus estimate, while revenue increased 4.2% year over year to approximately $1.13 billion. Illumina Reports Financial Results for Third Quarter
• Positive Sentiment: Full-year guidance was raised. Management increased its 2026 outlook, with revenue guidance of roughly $4.65 billion at the midpoint, supported by clinical sequencing demand and continued adoption of the NovaSeq X platform. ILMN Q3 Earnings Call Highlights
• Positive Sentiment: Long-term industry demand remains favorable. Recent market reports point to strong growth in clinical genomics, sequencing-as-a-service, population screening, and AI-enabled genomic analysis—markets in which Illumina is a major participant. These reports are industry forecasts rather than new company contracts or financial commitments.
• Neutral Sentiment: Analyst sentiment became more cautious. JPMorgan reduced its price target from $320 to $300, while Robert W. Baird maintained a Hold rating. The target cut suggests less near-term upside following Illumina’s substantial prior rally. JPMorgan Adjusts Price Target
• Negative Sentiment: Revenue performance disappointed investors. Although earnings surpassed estimates, quarterly revenue was below consensus in several reports, highlighting softer demand than expected and limiting the impact of the profit beat.
• Negative Sentiment: China exposure, tariffs, and business mix remain concerns. Investors are worried about China-related revenue challenges, tariff uncertainty, research-market weakness, and pricing pressure. A broader pullback in AI-linked technology stocks also hurt sentiment toward Illumina. Illumina Shares Tumble on China Woes

Insider Transactions at Illumina

In other Illumina news, Director Keith Meister sold 457,858 shares of the company’s stock in a transaction on Tuesday, August 4th. The shares were sold at an average price of $200.10, for a total transaction of $91,617,385.80. Following the sale, the director owned 2,372,694 shares of the company’s stock, valued at approximately $474,776,069.40. This represents a 16.18% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Insiders have sold a total of 2,061,235 shares of company stock valued at $436,356,102 in the last quarter. 2.90% of the stock is owned by insiders.

Illumina Price Performance

Shares of NASDAQ ILMN opened at $235.99 on Monday. The company has a market capitalization of $35.63 billion, a P/E ratio of 40.62, a price-to-earnings-growth ratio of 3.30 and a beta of 1.46. Illumina, Inc. has a 52-week low of $106.12 and a 52-week high of $309.35. The company has a debt-to-equity ratio of 0.57, a quick ratio of 2.05 and a current ratio of 2.63. The company’s 50 day moving average price is $249.30 and its 200-day moving average price is $176.18.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings data on Thursday, October 29th. The life sciences company reported $1.62 EPS for the quarter, beating analysts’ consensus estimates of $1.36 by $0.26. Illumina had a net margin of 19.72% and a return on equity of 28.38%. The company had revenue of $1.17 billion for the quarter, compared to analyst estimates of $1.15 billion. During the same period in the prior year, the firm posted $1.34 EPS. The company’s quarterly revenue was up 4.2% on a year-over-year basis. Equities analysts forecast that Illumina, Inc. will post 5.43 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on ILMN. Leerink Partners increased their price objective on Illumina from $220.00 to $300.00 and gave the company an “outperform” rating in a report on Tuesday, September 29th. Wall Street Zen raised Illumina from a “hold” rating to a “buy” rating in a report on Sunday, October 11th. Argus upped their price target on Illumina from $180.00 to $235.00 and gave the company a “buy” rating in a research report on Thursday, September 3rd. Deutsche Bank Aktiengesellschaft cut Illumina to a “hold” rating in a research note on Wednesday, August 5th. Finally, Guggenheim raised their price objective on Illumina from $226.00 to $305.00 and gave the stock a “buy” rating in a research report on Thursday, October 1st. Nine equities research analysts have rated the stock with a Buy rating, seven have given a Hold rating and three have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $238.53.

Illumina Profile

Illumina, Inc is a biotechnology company that develops and manufactures genomics and genetic-analysis technologies. Its products are used to study DNA and RNA in applications including biomedical research, clinical testing, pharmaceutical development, reproductive health, oncology and population genomics.

The company’s offerings include next-generation sequencing systems, consumable flow cells and reagent kits, microarrays, and genomic data-analysis software. Its sequencing portfolio includes instruments such as the NovaSeq, NextSeq, MiSeq and iSeq platforms, while its informatics products include the DRAGEN platform, which supports the processing and interpretation of sequencing data.